The BRCA1 is down‐regulated in CML patients, promoting abnormal mitosis and aneuploidy as well as altered DNA damage responses; studies have shown that BCR‐ABL strongly downregulates the BRCA1 protein levels (Wolanin et al., 2010). Here, BRCA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.